Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Spartalizumab is a humanized IgG4/κ mAb directed against human programmed cell death‐1 (PD‐1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n = 18) with a range of tumo...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Sci
Hoofdauteurs: Minami, Hironobu, Doi, Toshihiko, Toyoda, Masanori, Imamura, Yoshinori, Kiyota, Naomi, Mitsuma, Ayako, Shimokata, Tomoya, Naito, Yoichi, Matsubara, Nobuaki, Tajima, Takeshi, Tokushige, Kota, Ishihara, Kae, Cameron, Scott, Ando, Yuichi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2020
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7893979/
https://ncbi.nlm.nih.gov/pubmed/33031626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14678
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items